Cardiol Therapeutics, Inc.

Canaccord Genuity Acted as a Lead Left Bookrunner in a Confidentially Marketed Public Offering for Cardiol Therapeutics

Canaccord Genuity is pleased to announce that on November 3, 2021, Cardiol Therapeutics, Inc. (the “Company”) (Nasdaq:CRDL), priced its $50.2 million confidentially marketed public offering at a price of $3.07 per unit. The Company issued 16,350,000 shares of common stock. Each Unit will consist of one Class A common share in the capital of the Corporation (each, a "Unit Share") and one-half Class A common share purchase warrant of the Corporation (each whole Class A common share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Class A common share of the Company (each, a “Warrant Share”) at a price of US$3.75 per Warrant Share, subject to adjustment in certain events, for a period of 36 months following the closing date of the Offering.

Canaccord Genuity acted as Lead Left Bookrunner for the offering.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of CVD.

The Canaccord Genuity team consisted of Eugene Rozelman, Jason Sleeth, Jennifer Pardi, Tara Hartigan, Brian O’Connor, Len Sauer, Michael J. Graham, Michael Wright, Trina Wang, Tyler Chamberland, Esther Lee, Brooke Szczygiel, Max McLernon, Calvin Reif, Sean Pritchett, Matthew Kurgan and Catherine Gaunci.